

FOR IMMEDIATE RELEASE

PR Contact:

Jasmine Fielding
Schwartz Communications
781-684-6247

CERVICAL CANCER DETECTION RECEIVES HIGH-TECH HELP *Acupath Laboratories, Inc. Offers Physicians Advanced Cervical Cancer Screenings Through the Use of ThinPrep® Imaging System*

Plainview, N.Y.—September, 2008—Acupath Laboratories, Inc., an anatomic pathology and cancer genetics laboratory based in Long Island, New York, is crediting greater accuracy in their cervical cancer screenings with the recent implementation of the ThinPrep® Imaging System, the first fully integrated, interactive computer system to assist cytotechnologists and pathologists with the primary screening of ThinPrep® Pap slides.

“Acupath Laboratories is committed to improving patient care and cancer diagnostics through the use of the latest technology and testing available today,” says Dr. Alla Joutovsky, Director of Cytopathology of Acupath Laboratories, Inc. “Using the ThinPrep Imaging System offers significant advantages over previous screening methodologies and has been proven to enhance the quality of the specimen. As a result, designating this system as the standard in our practice was simply the next step toward increased cervical cancer detection.”

Approved by the U.S. Food and Drug Administration (FDA), the ThinPrep Imaging System combines revolutionary imaging technology with human interpretive expertise and has been proven to enhance cervical cancer screenings. If detected early, the disease is almost 100% curable. According to the American Cancer Society, nearly 11,000 women in the United States are currently affected by cervical cancer, and approximately 3,800 will succumb to the disease. Since January 2008, Acupath Laboratories has been offering patients the ThinPrep Pap Test—the only FDA approved method to replace the conventional Pap smear by means of a liquid-based test that employs a fluid medium to collect and preserve cervical cells. At least 30 published studies involving more than 500,000 patients have demonstrated the superior performance of the

ThinPrep Pap Test compared to that of the original Pap Smear, including a meta-analysis published in the *American Journal of Obstetrics and Gynecology*, which specifically found that the ThinPrep Pap Test enhances the diagnosis of low-grade (LSIL) and high-grade squamous intraepithelial lesions (HSIL) in addition to increased sample adequacy.

During the past 50 years, with the use of the conventional Pap Smear, nearly 80% of every cell sample was discarded when a physician threw away the swab or spatula during specimen collection. The ThinPrep Pap test, however, has vastly improved this collection process. Rather than smearing the cells on a slide and discarding the collection tool, the specimen is rinsed in a ThinPrep vial, capturing virtually all of the cells. The vial is then sent to the laboratory where a ThinPrep Processor eliminates obscuring debris for the cytopathologist.

About Acupath Laboratories, Inc.:

Acupath Laboratories, Inc. is a cutting-edge anatomic pathology and cancer genetics laboratory located in Plainview, NY that has established itself as a leader in the field of cancer diagnostics for its immediate delivery of accurate, comprehensive pathology, molecular and cytogenetic analysis. Our reputation is built on the foundation of our highly esteemed board-certified pathologists specializing in gynecologic pathology, a highly professional support staff and a state-of-the-art lab facility. Our entire staff is committed to fully and accurately meeting our patient's needs—every specimen, every time. For more information, visit www.acupath.com or call 1.888.ACUPATH (228-7284).

###